Leuprolide

Overview

The definitive demonstration that dosing pattern determines direction. Leuprolide is a more potent GnRH agonist than the natural hormone — and because it is given continuously rather than in pulses, it shuts the reproductive axis down instead of switching it on.

How it works

Continuous GnRH receptor occupancy causes receptor downregulation and pituitary desensitisation after an initial surge. LH and FSH fall, and gonadal steroid production drops to castrate levels within 2–4 weeks. Pulsatile GnRH, by contrast, stimulates the axis — which is why gonadorelin and leuprolide have opposite clinical effects.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• Decades of randomized trials across four distinct approved indications.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Effective androgen deprivation in prostate cancer Strong evidence

  Achieves castrate testosterone levels reliably, a cornerstone of advanced prostate cancer treatment.

• Halts central precocious puberty Strong evidence

  Arrests premature pubertal progression and preserves adult height potential, with the effect reversing on discontinuation.

• Reduces endometriosis pain and fibroid volume Strong evidence

  Randomized evidence in both indications.

• Long-acting depot formulations Strong evidence

  Dosing intervals from one to six months substantially improve adherence.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Testosterone flare in the first two weeks Serious

  The initial agonist surge can worsen prostate cancer symptoms, causing spinal cord compression or urinary obstruction. Anti-androgen cover is required in patients at risk.

• Bone mineral density loss Serious

  Sustained hypogonadism causes progressive bone loss and osteoporotic fracture risk with long-term use.

• Cardiometabolic effects Serious

  Androgen deprivation is associated with insulin resistance, dyslipidaemia and increased cardiovascular risk.

• Vasomotor and sexual side effects Moderate evidence

  Hot flushes, loss of libido and erectile dysfunction are near-universal in men.

• Mood effects Moderate evidence

  Depression and emotional lability are commonly reported, and specifically flagged in pediatric use.

• Fetal harm Serious

  Contraindicated in pregnancy.

• Add-back therapy usually required Moderate evidence

  For endometriosis and fibroids, hormonal add-back is standard to limit bone loss, which complicates the regimen.

Who should avoid it

• Pregnancy and breastfeeding
• Undiagnosed abnormal vaginal bleeding
• Known hypersensitivity to GnRH analogs
• Caution with pre-existing osteoporosis

If used under medical supervision, monitor

• Testosterone and PSA in prostate cancer
• Bone mineral density with therapy beyond 6 months
• Glucose, HbA1c and lipids
• Growth velocity and bone age in pediatric use
• Mood assessment

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• Drugs that prolong QT — androgen deprivation adds risk
• Antihyperglycemic agents — requirements often increase

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Regulatory & legal status

Prescription drug.

Infographic

Leuprolide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Leuprolide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Hormonal & Reproductive